Good Ndews for Premenopausal HR+ HER2- Patients!

Bestbird

If you are pre- or perimenopausal and have hormone receptor positive, HER2- MBC for which you have not yet had endocrine therapy, you'll want to read this!


At ASCO 2019, it was disclosed that adding Kisqali (Ribociclib) to hormonal therapy for pre- and perimenopausal hormone receptor positive, HER2 negative patients significantly increased Overall Survival (OS). These findings are based upon the the MONALEESA-7 study, which enrolled 672 pre- and peri-menopausal patients who had not received prior hormonal therapy, The patients were randomized to receive either Kisqali or a placebo in combination with Tamoxifen (or Letrozole or Aromasin) and Zoladex, an ovarian suppression drug.


The study determined that the Kisqali combination resulted in 70.2% Overall Survival (OS) at 42 months vs. 46% OS in patients receiving hormone therapy without Kisqali. This corresponds to a 29% lower risk of death in patients receiving the Kisqali combination therapy.


Kisqali in combination with endocrine therapy has been approved in the US, Canada, Europe, and Australia (and potentially other countries) for pre- or perimenopausal patients who have hormone receptor positive, HER2- MBC. From: https://www.eurekalert.org/pub_releases/2019-06/uotm-rph053019.php


This and other information about approved treatments and cutting edge research can be found in my book, "The Insider's Guide to Metastatic Breast Cancer," which is also available in a complimentary .pdf. For more information, please visit: https://www.insidersguidembc.com/about